Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy

Abstract

Objective: To determine the efficacy and safety of paclitaxel given as a three-hour infusion in patients with metastatic breast cancer which had progressed despite hormonal therapy and/or chemotherapy. Design and setting: Multicentre phase II trial undertaken in five major centres or hospitals in Sydney, Melbourne and Adelaide. Patients and methods: 50 patients with clinically or radiologically measurable or evaluable metastatic breast cancer recruited between March and July 1993. All had received prior chemotherapy, with subsequent disease progression. Intervention: Paclitaxel (Anzatax, Faulding) was given at a dose of 175 mg/m2 intravenously over three hours every three weeks for up to nin..